微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 34.3% | -5.32% | -3.01% | 103/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 35.36% | -2.13% | 2.17% | 101/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 34.61% | 1.28% | -3.95% | 100/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 36.04% | -10.2% | -0.53% | 103/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 36.23% | -9.73% | 0.27% | 100/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 36.13% | -11.05% | 5.72% | 103/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 34.17% | -23.2% | -14.84% | 103/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 40.13% | -8.22% | 0% | 103/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 40.13% | -5.21% | -1.2% | 97/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 40.62% | -5.83% | -8.72% | 95/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 44.5% | 4.24% | 1.77% | 87/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 43.73% | -5.4% | 3.28% | 96/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 42.34% | -9.61% | -1.85% | 97/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 43.13% | -3.16% | 1.05% | 95/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 42.69% | -1.15% | -7.65% | 94/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 46.22% | -12.15% | -1.31% | 89/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 46.84% | -13.31% | 5.14% | 83/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 44.54% | -19.44% | 3.15% | 90/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 43.19% | -22.38% | -17.92% | 88/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 52.62% | -9.47% | -2.62% | 78/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 54.03% | -8.22% | -2.29% | 66/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 55.29% | -1.27% | -0.61% | 70/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 55.63% | 6.43% | -4.28% | 61/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 58.12% | -0.6% | -1.27% | 63/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 58.87% | 0.9% | 5.12% | 52/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 56% | -5.31% | 7.14% | 59/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 52.27% | -6.07% | -10.6% | 57/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 58.47% | 16.79% | 0.22% | 63/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 58.34% | 25.77% | -1.35% | 51/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 59.14% | 37.53% | 6.28% | 51/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 55.65% | 36.41% | 11.16% | 52/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 50.07% | 40.32% | 7.93% | 70/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 46.39% | 43.81% | 7.87% | 59/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 43% | 41.77% | 5.41% | 67/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 40.8% | 52.55% | 14.34% | 69/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 35.68% | 28.09% | 10.62% | 88/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 32.26% | 3.22% | 6.34% | 71/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 30.33% | -7.48% | 13.42% | 80/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 26.74% | -16.76% | -3.99% | 71/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 27.86% | -21.01% | -10.86% | 92/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 31.25% | -10.17% | -4.69% | 59/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 32.79% | -5.04% | 2.05% | 66/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 32.13% | -3.77% | -8.9% | 54/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |